Log in
Log into your PedsMrkt account to access our Community forums.
If you don't see an email, please check your Junk folder. The email will be sent from support@pedsmrkt.com
IP License - FOXP3+ Helios+ Engineered Regulatory T cells
IP Licensing
For informational purposes only. Please contact seller directly for more details.
Share This:
Children’s Mercy Kansas City, together with the University of Kansas, has developed a novel cell-based therapy to combat disordered inflammation. Using a novel method, CD4+ and CD8+ regulatory T cells have been engineered to over express both FOXP3 and Helios without suppression of either product. Efficacy of the eTregs has been shown in vitro and in a humanized model of graft versus host disease (GVHD). CD4+ and CD8+ cells can be separated if preferred.
This innovation is applicable in the treatment of diseases in which it is desirable to reduce inflammatory immune response such as type 1 diabetes, multiple sclerosis, allograft/transplant rejection, inflammatory bowel disease, lupus, rheumatoid arthritis, and other chronic inflammatory diseases. If interested in licensing and/or research collaborations, contact Children’s Mercy Kansas City to have discussions. US Patent Issued, Second US and International patents pending.
Shipping Information
Digital delivery/downloads will typically be delivered within 2 business days.
Add to Cart: Physical products typically take 5-8 business days. You will receive an order confirmation email from PedsMrkt followed by a shipping email when your order ships.
Please contact the seller directly with any questions about your order.
Returns
Please contact the seller directly for their return policy and to
handle returns. Customer will be responsible for return shipping fees.
